NCT00193102终止2 期
Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 40
- 主要终点
- Overall response rate
研究概览
简要总结
The lack of non-overlapping toxicities between the two drugs, the ease of all oral drug administration, and the possibility for antitumor synergy make exploration of this combination regimen attractive in women with previously treated metastatic breast cancer. This phase II trial will be performed in collaboration with the Minnie Pearl Cancer Research Network, a multicenter, community-based clinical trials group.
详细描述
Upon determination of eligibility, patients will be receive:
Thalidomide + Capecitebine
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •To be included in this study, you must meet the following criteria:
- •Metastatic breast cancer confirmed by biopsy
- •Measurable or evaluable disease
- •Females > 18 years
- •Able to perform activities of daily living with minimal assistance
- •Life expectancy > 3 months
- •Adequate bone marrow, liver and kidney function
- •All patients must give written informed consent in order to participate.
排除标准
- •You cannot participate in this study if any of the following apply to you:
- •Women who are pregnant or lactating.
- •Received more than 3 prior chemotherapy regimens in the metastatic setting.
- •Received continuous infusion 5-fluorouracil lasting > 120 hours.
- •Received thalidomide or capecitabine as their last prior regimen.
- •Preexisting moderate to severe neuropathy
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
结局指标
主要结局
Overall response rate
时间窗: 18 Months
次要结局
未报告次要终点
研究者
相似试验
尚未招募
3 期
se of medicines- Hydroxyurea and thalidomide for children suffering from thalassemiaCTRI/2023/12/060945ICMR, Delhi
已完成
2 期
Thalidomide in Combination With Temodar in Patients With Neuroendocrine TumorsNeuroendocrine TumorNCT00165230Dana-Farber Cancer Institute32
进行中（未招募）
1 期
Phase II study of thalidomide in combination with temozolomide in metastatic malignant melanoma with brain metastases - Tem-ThalAdvanced metastic malignant melanomaEUCTR2004-005164-25-DKOdense University Hospital40
已完成
2 期
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT00538733Weill Medical College of Cornell University26
已完成
2 期
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate CancerProstatic NeoplasmNCT00001446National Cancer Institute (NCI)64